Efficacy of subconjunctival bevacizumab injection in corneal neovascularisation.

Aim: To evaluate the therapeutic effect of subconjunctival Bevacizumabon corneal neovascularisation Design: A prospective randomized noncomparative study. Method: The charts of 10 consecutive patients with corneal neovascularisation who received single S.C. inj. of Bevacizumab (2.5mg/0.1ml) were reviewed. Digital photographs of the cornea were taken pre & post injection & then at 1 wk,3wk & 2months duration. Digital photographs of the cornea were analyzed to determine the length, density, extent, centricity of corneal neovascularisation and the area of cornea covered by neovascularisation as a percentage of the total corneal area. Results: Subconjunctival injection of Bevacizumab (Avastin) caused significant regression of corneal neovascularisation in 1 pt, partial regression in 6 pts and no effect in 3 pts as measured by length and surface area of neovascularisation. No significant ocular or systemic complications were found. Conclusion: Subconjunctival inj. of Bevacizumab is effective in regressing corneal neovascularisation.